What are the drug interaction risks when combining Auvelity (dextromethorphan‑bupropion) with Concerta (methylphenidate)?

Auvelity and Concerta Interactions

The combination of Auvelity (dextromethorphan-bupropion) and Concerta (methylphenidate) can be used together without significant pharmacokinetic interactions, but requires monitoring for additive cardiovascular effects and seizure risk from the bupropion component.

Key Interaction Profile

Pharmacokinetic Interactions: Minimal Risk

The most relevant evidence directly addressing this combination shows no metabolic interaction between methylphenidate and dextromethorphan 1. In vitro studies demonstrated that dl-methylphenidate did not inhibit dextrorphan formation (the metabolite of dextromethorphan), and methylphenidate metabolism was unaffected by dextromethorphan or its metabolites 1. This is reassuring since the dextromethorphan component of Auvelity relies on CYP2D6 metabolism, which methylphenidate does not significantly affect.

Pharmacodynamic Concerns: Moderate Risk

The primary concerns with this combination are additive pharmacodynamic effects rather than metabolic interactions:

1. Cardiovascular Effects (Primary Concern)

• Both medications can increase blood pressure and heart rate 2
• Auvelity carries warnings about increased blood pressure and hypertension 2
• Methylphenidate is a sympathomimetic stimulant with known cardiovascular effects
• Monitor blood pressure and pulse at baseline and regularly during treatment
• Avoid this combination in patients with uncontrolled hypertension, recent MI, or serious arrhythmias

2. Seizure Risk (Secondary Concern)

• Bupropion (component of Auvelity) is associated with dose-dependent seizure risk 3
• Methylphenidate can lower seizure threshold in susceptible individuals
• Use caution in patients with seizure history, eating disorders, or abrupt alcohol/benzodiazepine discontinuation
• The seizure risk with Auvelity is dose-related, making adherence to dosing guidelines critical 2

3. Psychiatric Activation

• Both agents can cause activation of mania/hypomania 2
• Monitor for psychosis, agitation, or mood destabilization
• Screen for bipolar disorder before initiating

Clinical Management Algorithm

When combining these medications:

1. Baseline Assessment:

   • Blood pressure and heart rate
   • Seizure history and risk factors
   • Bipolar disorder screening
   • Current cardiovascular status

2. Monitoring Schedule:

   • Weekly BP/HR for first month
   • Monthly thereafter
   • Assess for psychiatric symptoms at each visit

3. Dosing Considerations:

   • Start Auvelity at standard dose: 1 tablet (45 mg dextromethorphan/105 mg bupropion) once daily for 3 days, then twice daily 2
   • Do not exceed maximum Auvelity dose (2 tablets daily)
   • Maintain stable methylphenidate dose when initiating Auvelity

Important Caveats

• The lack of metabolic interaction does NOT mean the combination is risk-free - the additive cardiovascular and CNS effects require vigilance
• One case report documented a potential interaction between cyclosporine and methylphenidate, but this involved immunosuppressants and is not directly relevant to the Auvelity combination 4
• The evidence base specifically for this combination is limited to in vitro studies; real-world clinical experience is still accumulating given Auvelity's recent approval (2022) 5

Contraindications to Combination

Avoid combining if patient has:

• Uncontrolled hypertension
• Recent cardiovascular event
• Active seizure disorder
• Concurrent MAOI use (14-day washout required) 2
• Known hypersensitivity to either agent

The combination is pharmacologically feasible but requires proactive monitoring for additive stimulant effects rather than concerns about drug metabolism alterations.